Revisiting Zynerba Pharmaceuticals


  • Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.
  • The company is advancing its primary drug candidate Zygel across several indications and the shares trade near the company’s cash balance.
  • A full investment analysis is presented in the paragraphs below.

Scientist analyzing medical sample in laboratory

Morsa Images/DigitalVision via Getty Images

“There is no complexity in what is, but only in the many escapes that we seek.” – Jiddu Krishnamurti

Today, we are looking back in on Zynerba Pharmaceuticals (NASDAQ:ZYNE) for the first time since

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ZYNE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I own a small holding of ZYNE through a covered call position.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Author’s note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum. Try a free 2-week trial today by clicking on our logo below!

Leave a Reply

Your email address will not be published. Required fields are marked *